SHARE

Esperion to acquire Corstasis for $75m upfront 

The PE-backed cardiometabolic and drug developer will buy Corstasis, maker of FDA-approved nasal spray diuretic Enbumyst, with the deal expected to close in Q2 2026 and potential $180m earn-outs.

Certification Note

Certified B Corporation” is a trademark licensed by B Lab, a private non-profit organization, to companies like ours that have successfully completed the B Impact Assessment (“BIA”) and therefore meet the requirements set by B Lab for social and environmental performance, accountability, and transparency. It is specified that B Lab is not a conformity assessment body as defined by Regulation (EU) No 765/2008, nor is it a national, European, or international standardization body as per Regulation (EU) No 1025/2012. The criteria of the BIA are distinct and independent from the harmonized standards resulting from ISO norms or other standardization bodies, and they are not ratified by national or European public institutions.